Ruby Mhajan, RPh

The second part of a comprehensive review of the specialty pharmaceuticals approved by the FDA in 2017.

Specialty pharmaceuticals featured prominently in the actions of the FDA in 2017.

A comprehensive review of new oncology molecular entities and previously approved oncology drugs that received expanded indications in 2016, as well as drugs approved in the final days of the year.

Although there were not as many new specialty drug approvals in 2016, there were many already-approved specialty medications that received expanded indications.

The second article in a two-part series examines oncology drug approvals and late-breaking FDA actions.

Part one of a two-part overview recapping significant drugs approved over the last year.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.